Zydus Worldwide DMCC acquires Assertio Holdings, Inc. (2026)

Deal facts

Buyer: Zydus Worldwide DMCC
Target: Assertio Holdings, Inc.
Deal value: Not disclosed
Announced: 13 May 2026
Status: Completed
Sector: Healthcare
Country: United States
Consideration: cash

Sources

What we know

Zydus Worldwide DMCC has agreed to acquire Assertio Holdings, Inc. in a going private transaction valued at an undisclosed amount. The deal, announced on 13 May 2026, was structured as a cash consideration purchase. Zydus Worldwide DMCC, a buyer based in the United Arab Emirates, acquired the US-based healthcare company. The transaction was completed on 16 June 2026, marking the end of the public listing for the target entity.

This acquisition represents a significant shift in ownership for the pharmaceutical firm, moving it from public markets to private control under the new parent company. The deal involved a straightforward exchange of cash for equity, with no complex merger structures or alternative consideration types reported. Regulatory approvals were secured to facilitate the finalisation of the purchase. The transaction is now fully completed.

More M&A Tools

Explore the Toolkit

Tools, frameworks and AI assistants designed for entrepreneurs serious about M&A.

Access now

Deal timeline

1 update

16 Jun 2026CompletedClosed
Zydus Worldwide DMCC completes acquisition of Assertio Holdings, Inc.
Introductory Note. As previously disclosed in the Current Report on Form 8-K filed with the Securities and Exchange Commission (the “ SEC ”) on May 13, 2026 by Assertio Holdings, Inc., a Delaware corporation (the “ Company ”), the Company entered into an Agreement and Plan of Merger (the “ Merger Agreement ”), dated as of May 13, 2026, with Zydus Worldwide DMCC, a limited liability company incorpo
Source

OpinionExit Mode editorial

We see a clear signal in the completion of the acquisition of Assertio Holdings, Inc by Zydus Worldwide DMCC. This transaction moves a US healthcare entity into private ownership under a buyer based in the United Arab Emirates. The deal structure is straightforward, relying entirely on cash consideration to effect the transfer of control. For the SME founder watching from the sidelines, this illustrates a distinct path where international capital seeks to take public companies private, removing the pressure of quarterly reporting and short-term market sentiment.

The shift from public to private status in the healthcare sector often invites scrutiny from competition authorities, particularly when cross-border elements are involved. While the specific regulatory hurdles for this deal are not detailed in the public record, the mechanics of such a move invariably require careful navigation of antitrust thresholds and change-of-control covenants. The buyer, operating from a free zone entity in Dubai, brings a different capital structure to the table than a traditional US or UK acquirer. This arrangement allows the target to operate with a longer-term strategic horizon, free from the immediate demands of public shareholders. The cash nature of the consideration provides certainty that is often missing in stock-based deals, though it also means the seller takes no part in any future upside.

Our view is that this deal highlights the growing appetite for cross-border consolidation in healthcare, driven by the need for capital and operational scale. The decision to go private suggests that the target company may have faced challenges in the public markets that a private owner could resolve more effectively. For founders considering their own exit strategies, the lesson is not just about finding a buyer, but finding the right type of buyer with the right capital structure. The absence of a disclosed value in the announcement is notable, yet the completion status confirms that terms were agreed upon and executed.

You should review your current capital structure this week to identify if public market pressures are hindering your long-term strategic goals. Determine whether a private equity partner or an international strategic buyer could offer the stability and cash resources needed to accelerate your growth without the distraction of daily share price fluctuations.

Editorial opinion. Not financial or legal advice.

Explore

Browse adjacent archives

Jump from this deal into the sector, buyer, deal type, and year views that carry the strongest contextual signal.

More Healthcare deals More 2026 deals More going private deals More from Zydus Worldwide DMCC All M&A deals

Similar deals

Other Healthcare M&A activity tracked by Exit Mode.

28 July 2026CompletedHealthcare

CCP PAW 2 LIMITED to acquire ANIMALCARE GROUP PLC

CCP PAW 2 Limited has agreed to acquire Animalcare Group Plc in a going private transaction. The deal was announced and completed on 30 July 2026. Both the buyer and the…

Buyer: CCP PAW 2 LIMITED
Target: ANIMALCARE GROUP PLC
Deal value: Not disclosed
Deal type: going private

Read deal Healthcare deals going private deals United Kingdom deals

26 July 2026CompletedHealthcare

argenx BV to acquire Forte Biosciences, Inc.

argenx BV has agreed to acquire Forte Biosciences, Inc. in a going private transaction valued at USD 2.2 billion. The Belgian listed biotechnology company is purchasing…

Buyer: argenx BV
Target: Forte Biosciences, Inc.
Deal value: USD 2,200,000,000
Deal type: going private

Read deal Healthcare deals going private deals United States deals

6 July 2026CompletedHealthcare

Vertex Pharmaceuticals Incorporated to acquire Crinetics Pharmaceuticals, Inc.

Vertex Pharmaceuticals Incorporated has agreed to acquire Crinetics Pharmaceuticals, Inc. in a going private transaction valued at $10 billion. The deal, announced on 6…

Buyer: Vertex Pharmaceuticals Incorporated
Target: Crinetics Pharmaceuticals, Inc.
Deal value: USD 10,000,000,000
Deal type: going private

Read deal Healthcare deals going private deals United States deals

6 July 2026CompletedHealthcare

Trafalgar Asset Management, LLC to acquire The Greater Cannabis Company, Inc.

Trafalgar Asset Management, LLC has agreed to acquire The Greater Cannabis Company, Inc. in a going private transaction. The deal was announced on 6 July 2026, following…

Buyer: Trafalgar Asset Management, LLC
Target: The Greater Cannabis Company, Inc.
Deal value: Not disclosed
Deal type: going private

Read deal Healthcare deals going private deals United States deals

30 June 2026CompletedHealthcare

Hanmi Pharmaceuticals Co. Ltd. to acquire Aptose Biosciences Inc.

Hanmi Pharmaceuticals Co. Ltd. has agreed to acquire Aptose Biosciences Inc. in a going private transaction valued at USD 3,466,470. The consideration for this deal cons…

Buyer: Hanmi Pharmaceuticals Co. Ltd.
Target: Aptose Biosciences Inc.
Deal value: USD 3,466,470
Deal type: going private

Read deal Healthcare deals going private deals Canada deals

Buyer history